Quality not sufficient samples on next-generation sequencing platforms analyzed on MassARRAY® and actionable mutations were identified
, /PRNewswire/ — Precision for Medicine, a leading next-generation provider of drug development research and services, today announced a strategic partnership with Agena Bioscience that helps bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. Precision for Medicine and Agena Bioscience will present cutting-edge findings on profiling challenging lung tumor samples at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, held November 19-23, 2024.
Precision for Medicine’s robust biospecimen inventory played a pivotal role in this study, which utilized lung tumor samples previously deemed quality not sufficient (QNS) or failed on NGS platforms. With Agena Bioscience’s advanced MassARRAY® technology and Precision for Medicine’s deeply characterized samples, actionable mutations were identified in 40% of cases, showcasing the transformative potential of this collaboration and advanced analytical capabilities.
“By delivering pre-characterized biospecimens with …